A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | |||||||||||||||
2 | ΝΕΟΠΛΑΣΜΑΤΑ ΟΛΩΝ ΤΩΝ ΣΥΣΤΗΜΑΤΩΝ ΚΑΙ ΛΕΥΧΑΙΜΙΩΝ | ||||||||||||||
3 | L01 AΝΤΙΝΕΟΠΛΑΣΜΑΤΙΚΑ ΦΑΡΜΑΚΑ | 75 | 90 | 100 | |||||||||||
4 | L01A Aλκυλιούντες παράγοντες | Νεοπλασίες όλων των συστημάτων και λευχαιμίες | |||||||||||||
5 | L01AA Aνάλογα του αζωθυπερίτη | ||||||||||||||
6 | L01AA01 CYCLOPHOSPHAMIDE MONOHYDRATE | συμμετοχή 10% για ένδειξη μυασθένεια και ΣΕΛ | |||||||||||||
7 | 11501 | 2 | ENDOXAN | C.TAB | 50MG/TAB | BTX50[BLIST(ALUM/PVC | BAXTER HELLAS ΕΠΕ | Χ* | |||||||
8 | 11504 | 2 | ENDOXAN | PD.INJ.SOL | 500MG/VIAL | BTX1 VIAL | BAXTER HELLAS ΕΠΕ | Χ* | |||||||
9 | 11505 | 1 | ENDOXAN | PD.INJ.SOL | 1000MG/VIAL | BTx1VIALS | BAXTER HELLAS ΕΠΕ | Χ* | |||||||
10 | L01AA06 IFOSFAMIDE | ||||||||||||||
11 | 1634001 | 1 | HOLOXAN | PD.SOL.INF | 1000MG/VIAL | BTX1VIAL | BAXTER HELLAS ΕΠΕ | Χ* | |||||||
12 | 1634003 | 1 | HOLOXAN | PD.SOL.INF | 2000MG/VIAL | BTX1VIAL | BAXTER HELLAS ΕΠΕ | Χ* | |||||||
13 | 1634004 | 1 | HOLOXAN | PD.SOL.INF | 500MG/VIAL | BTX1VIAL | BAXTER HELLAS ΕΠΕ | Χ* | |||||||
14 | L01AB Aλκυλοσουλφονικές ενώσεις | 75 | 90 | 100 | |||||||||||
15 | L01AB01 BUSULFAN | ||||||||||||||
16 | 2646101 | 2 | BUSILVEX | C/S.SOL.IN | 6MG/ML | BTx 8 VIALS x 10 ML | PIERRE FABRE MEDICAMENT PRODUCTION, FRANCE | Χ | |||||||
17 | L01AD Nιτροζουρίες | 75 | 90 | 100 | |||||||||||
18 | L01AD01 CARMUSTINE | ||||||||||||||
19 | 2451101 | 1 | GLIADEL | IMPLANT | 7,7MG/IMPLANT | BTX8 IMPLANTS | MGI PHARMA LTD, UNITED KINGDOM | Χ | |||||||
20 | L01AD05 FOTEMUSTINE | ||||||||||||||
21 | 2251801 | 1 | MUPHORAN | PS.SOL.INF | PS.SOL.INF,208MG/VIA | BTX1VIAL+1AMPX4ML | ΣΕΡΒΙΕ ΕΛΛΑΣ ΦΑΡΜΑΚΕΥΤΙΚΗ Ε.Π.Ε. | Χ | |||||||
22 | L01AX Άλλοι αλκυλιούντες παράγοντες | 75 | 90 | 100 | |||||||||||
23 | L01AX03 TEMOZOLOMIDE | ||||||||||||||
24 | 2411401 | 1 | TEMODAL | CAPS | 5MG/CAP | BTX5 | SP EUROPE, BELGIUM | Χ | |||||||
25 | 2411401 | 2 | TEMODAL | CAPS | 5MG/CAP | BTX20 | SP EUROPE, BELGIUM | Χ | |||||||
26 | 2411402 | 1 | TEMODAL | CAPS | 20MG/CAP | BTX5 | SP EUROPE, BELGIUM | Χ | |||||||
27 | 2411402 | 2 | TEMODAL | CAPS | 20MG/CAP | BTX20 | SP EUROPE, BELGIUM | Χ | |||||||
28 | 2411403 | 1 | TEMODAL | CAPS | 100MG/CAP | BTX5 | SP EUROPE, BELGIUM | Χ | |||||||
29 | 2411404 | 1 | TEMODAL | CAPS | 250MG/CAP | BTX5 | SP EUROPE, BELGIUM | Χ | |||||||
30 | 2411405 | 1 | TEMODAL | CAPS | 140MG/CAP | Γυάλινο φιαλίδιο x5 CAPS | SP EUROPE, BELGIUM | Χ | |||||||
31 | 2411405 | 2 | TEMODAL | CAPS | 140MG/CAP | Γυάλινο φιαλίδιο x20 CAPS | SP EUROPE, BELGIUM | Χ | |||||||
32 | 2411406 | 1 | TEMODAL | CAPS | 180MG/CAP | Γυάλινο φιαλίδιο x5 CAPS | SP EUROPE, BELGIUM | Χ | |||||||
33 | 2411407 | 1 | TEMODAL | PD.SOL.INF | 2,5MG/ML | ΒΤx 1 BOTTLE | SP EUROPE, BELGIUM | Χ | |||||||
34 | 2411401 | 3 | TEMODAL | CAPS | 5MG/CAP | (PET/ALU/PET)x5 | SP EUROPE, BELGIUM | X | |||||||
35 | 2411402 | 3 | TEMODAL | CAPS | 20MG/CAP | BTx 5 σε ατομικούς φακελλίσκους | SP EUROPE, BELGIUM | X | |||||||
36 | 2411403 | 3 | TEMODAL | CAPS | 100MG/CAP | BTx 5 σε ατομικούς φακελλίσκους | SP EUROPE, BELGIUM | X | |||||||
37 | 2411404 | 3 | TEMODAL | CAPS | 250MG/CAP | BTx 5 σε ατομικούς φακελλίσκους | SP EUROPE, BELGIUM | X | |||||||
38 | 2411405 | 3 | TEMODAL | CAPS | 140MG/CAP | BTx 5 σε ατομικούς φακελλίσκους | SP EUROPE, BELGIUM | X | |||||||
39 | 2411406 | 3 | TEMODAL | CAPS | 180MG/CAP | BTx 5 σε ατομικούς φακελλίσκους | SP EUROPE, BELGIUM | X | |||||||
40 | 2938301 | 1 | TEMOZOLOMIDE/TEVA | CAPS | 5MG/CAP | Φιάληx5(γυάλινη) | TEVA PHARMA B.V., UTRECHT, THE NETHERLANDS | X | |||||||
41 | 2938301 | 2 | TEMOZOLOMIDE/TEVA | CAPS | 5MG/CAP | Φιάληx20(γυάλινη) | TEVA PHARMA B.V., UTRECHT, THE NETHERLANDS | X | |||||||
42 | 2938302 | 1 | TEMOZOLOMIDE/TEVA | CAPS | 20MG/CAP | Φιάληx5(γυάλινη) | TEVA PHARMA B.V., UTRECHT, THE NETHERLANDS | X | |||||||
43 | 2938302 | 2 | TEMOZOLOMIDE/TEVA | CAPS | 20MG/CAP | Φιάληx20(γυάλινη) | TEVA PHARMA B.V., UTRECHT, THE NETHERLANDS | X | |||||||
44 | 2938303 | 1 | TEMOZOLOMIDE/TEVA | CAPS | 100MG/CAP | Φιάληx5(γυάλινη) | TEVA PHARMA B.V., UTRECHT, THE NETHERLANDS | X | |||||||
45 | 2938304 | 1 | TEMOZOLOMIDE/TEVA | CAPS | 140MG/CAP | Φιάληx5(γυάλινη) | TEVA PHARMA B.V., UTRECHT, THE NETHERLANDS | X | |||||||
46 | 2938304 | 2 | TEMOZOLOMIDE/TEVA | CAPS | 140MG/CAP | Φιάληx20(γυάλινη) | TEVA PHARMA B.V., UTRECHT, THE NETHERLANDS | X | |||||||
47 | 2938305 | 1 | TEMOZOLOMIDE/TEVA | CAPS | 180MG/CAP | Φιάληx5(γυάλινη) | TEVA PHARMA B.V., UTRECHT, THE NETHERLANDS | X | |||||||
48 | 2938306 | 1 | TEMOZOLOMIDE/TEVA | CAPS | 250MG/CAP | Φιάληx5(γυάλινη) | TEVA PHARMA B.V., UTRECHT, THE NETHERLANDS | X | |||||||
49 | L01AX04 DACARBAZINE | ||||||||||||||
50 | 1662201 | 1 | DETICENE | PS.SOL.INF | 100MG/VIAL | BTx1VIAL+10ML SOLV | SANOFI-AVENTIS AEBE | Χ | |||||||
51 | L01B Aντιμεταβολίτες | 75 | 90 | 100 | |||||||||||
52 | L01BA Aνάλογα φυλλικού οξέος | ||||||||||||||
53 | L01BA01 METHOTREXATE | Για την ένδειξη ρευματοειδης αρθρίτιδα η συμμετοχή ασφαλισμένου είναι 10% | |||||||||||||
54 | 1760701 | 1 | EMTHEXATE | INJ.SOL | 5MG/2ML VIAL | ΒΤΧ1VIALX2ML | CHEMIPHARM Σ.Γ. ΝΤΕΤΣΑΒΕΣ & ΣΙΑ Ε.Ε. | Χ* | |||||||
55 | 1760701 | 2 | EMTHEXATE | INJ.SOL | 5MG/2ML VIAL | ΒΤΧ25VIALSX2ML | CHEMIPHARM Σ.Γ. ΝΤΕΤΣΑΒΕΣ & ΣΙΑ Ε.Ε. | Χ* | |||||||
56 | 1760702 | 1 | EMTHEXATE | INJ.SOL | 50MG/2ML VIAL | ΒΤΧ1VIALX2 ML | CHEMIPHARM Σ.Γ. ΝΤΕΤΣΑΒΕΣ & ΣΙΑ Ε.Ε. | Χ* | |||||||
57 | 1760705 | 1 | EMTHEXATE | INJ.SOL | 500MG/20ML VIAL | ΒΤΧ1VIALX20ML | CHEMIPHARM Σ.Γ. ΝΤΕΤΣΑΒΕΣ & ΣΙΑ Ε.Ε. | Χ* | |||||||
58 | 1760706 | 1 | EMTHEXATE | INJ.SOL | 1000MG/40ML VIAL | ΒΤΧ1VIALX40ML | CHEMIPHARM Σ.Γ. ΝΤΕΤΣΑΒΕΣ & ΣΙΑ Ε.Ε. | Χ* | |||||||
59 | 2699706 | 1 | METOJECT | INJ.SOL | 50MG/ML | BT x 1PF.SYR.x0,15ML | MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH | Χ* | |||||||
60 | 2699706 | 6 | METOJECT | INJ.SOL | 50MG/ML | BTx 1 PF.SYR.x0,20ML | MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH | Χ* | |||||||
61 | 2699706 | 11 | METOJECT | INJ.SOL | 50MG/ML | BTx 1 PF.SYR.x0,30ML | MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH | Χ* | |||||||
62 | 2699706 | 16 | METOJECT | INJ.SOL | 50MG/ML | BTx 1 PF.SYR.x0,40ML | MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH | Χ* | |||||||
63 | 302402 | 1 | METHOTREXATE/PFIZER | INJ.SO.INF | 1000MG/40ML | 1 BOTTLEx40 ML | PFIZER ΕΛΛΑΣ Α.Ε. | Χ* | |||||||
64 | L01BA04 PEMETREXED | ||||||||||||||
65 | 2667801 | 1 | ALIMTA | PD.C.SO.IN | 500MG/VIAL | BTX1VIAL | ELI-LILLY NEDERLAND B.V., THE NEDERLANDS | Χ | |||||||
66 | L01BB Aνάλογα πουρίνης | 75 | 90 | 100 | |||||||||||
67 | L01BB04 CLADRIBINE | ||||||||||||||
68 | 2221301 | 1 | LEUSTATIN | SOL.INF | 10MG/10ML | BTx7VIALSx10ML | JANSSEN-CILAG ΦΑΡΜΑΚΕΥΤΙΚΗ ΑΕΒΕ | Χ | |||||||
69 | L01BB05 FLUDARABINE PHOSPHATE | ||||||||||||||
70 | 2215401 | 1 | FLUDARA | PD.I.S.INF | 50MG/VIAL | BTx5 VIALS | GENZYME EUROPE B.V., HOLLAND | Χ | |||||||
71 | 2215402 | 2 | FLUDARA | F.C.TAB | 10MG/TAB | BTx20 (BLIST 4x5) | GENZYME EUROPE B.V., HOLLAND | Χ | |||||||
72 | 2754801 | 2 | FLUDARABIN/EBEWE | IN.SO.CR | 25MG/ML | BT x 5 VIALSx 2 ML | EBEWE PHARMA GES.M.B.H NFG.KG, AUSTRIA | Χ | |||||||
73 | 2708001 | 1 | FLUDARABINE/TEVA | C/S.SOL.IN | 25MG/ML | BTx1 VIALx 2 ML | CHEMIPHARM Σ.Γ. ΝΤΕΤΣΑΒΕΣ & ΣΙΑ Ε.Ε. | Χ | |||||||
74 | L01BB06 CLOFARABINE | ||||||||||||||
75 | 2860101 | 2 | EVOLTRA | C/S.SOL.IN | 20MG (1MG/ML) 20ML VIAL | BTx4 VIALS | GENZYME EUROPE B.V., HOLLAND | Χ | |||||||
76 | L01BB07 NELARABINE | ||||||||||||||
77 | 2791901 | 1 | ATRIANCE | SOL.INF | 5MG/ML | BTx6 VIALS x50 ML | GLAXO GROUP LTD ENGLAND | Χ | |||||||
78 | L01BC Aνάλογα πυριμιδίνης | 75 | 90 | 100 | |||||||||||
79 | L01BC01 CYTARABINE | ||||||||||||||
80 | 819801 | 1 | ARACYTIN | PS.INJ.SOL | 100MG/6ML VIAL | 1VIAL+1AMPx5ML SOLV | PFIZER ΕΛΛΑΣ Α.Ε. | Χ | |||||||
81 | 819802 | 1 | ARACYTIN | PS.INJ.SOL | 500MG/15ML VIAL | 1VIAL+1AMPx10MLSOLV | PFIZER ΕΛΛΑΣ Α.Ε. | Χ | |||||||
82 | L01BC02 FLUOROURACIL | ||||||||||||||
83 | 2379603 | 1 | FLUOROURACIL/EBEWE | INJ.SOL | 1000MG/20ML VIAL | BTX1VIALX20ML | ΦΑΡΜΑΝΕΛ ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε. | Χ | |||||||
84 | L01BC05 GEMCITABINE HYDROCHLORIDE | ||||||||||||||
85 | 2843801 | 1 | GEMCIPEN (ΓΕΝΟΣΗΜΟ) | PD.SOL.INF | 200MG/VIAL | BTx1VIAL | ΕΝΟΡΑΣΙΣ ΑΕ | Χ | |||||||
86 | 2843802 | 1 | GEMCIPEN (ΓΕΝΟΣΗΜΟ) | PD.SOL.INF | 1000MG/VIAL | BTx1VIAL | ΕΝΟΡΑΣΙΣ ΑΕ | Χ | |||||||
87 | 2814001 | 1 | GEMCITABINE/MEDAC | PD.SOL.INF | 38MG/1ML | BTx 200MG/ VIAL | MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH | Χ | |||||||
88 | 2814001 | 2 | GEMCITABINE/MEDAC | PD.SOL.INF | 38MG/1ML | BTx1000MG/ VIAL | MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH | Χ | |||||||
89 | 2814001 | 3 | GEMCITABINE/MEDAC | PD.SOL.INF | 38MG/1ML | BTx 1500MG/ VIAL | MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH | Χ | |||||||
90 | 2863001 | 1 | GEMNIL | PD.SOL.INF | 200MG/VIAL | BT x 1 GLASS VIAL | VIANEX A.E. | Χ | |||||||
91 | 2863002 | 1 | GEMNIL | PD.SOL.INF | 1000MG/VIAL | BT x 1 GLASS VIAL | VIANEX A.E. | Χ | |||||||
92 | 2830101 | 1 | SANTABIN (ΓΕΝΟΣΗΜΟ) | PD.SOL.INF | 200MG/VIAL | BTx1 VIAL | SANTA PHARMA A.E. | Χ | |||||||
93 | 2830102 | 1 | SANTABIN (ΓΕΝΟΣΗΜΟ) | PD.SOL.INF | 1000MG/VIAL | BTx1 VIAL | SANTA PHARMA A.E. | Χ | |||||||
94 | 2242901 | 1 | ΓΚΕΜΖΑΡ | PD.SOL.INF | 200MG/VIAL | BTx1VIAL | ΦΑΡΜΑΣΕΡΒ ΛΙΛΛΥ Α.Ε.Β.Ε. | Χ | |||||||
95 | 2242902 | 1 | ΓΚΕΜΖΑΡ | PD.SOL.INF | 1000MG/VIAL | BTx 1 VIAL | ΦΑΡΜΑΣΕΡΒ ΛΙΛΛΥ Α.Ε.Β.Ε. | Χ | |||||||
96 | 2841001 | 1 | GEMCIRENA | PD.SOL.INF | 38MG/ML | BTx1 VIALx200 MG | FRESENIUS KABI HELLAS AE | Χ | |||||||
97 | 2841001 | 2 | GEMCIRENA | PD.SOL.INF | 38MG/ML | BTx1 VIALx1000 MG | FRESENIUS KABI HELLAS AE | Χ | |||||||
98 | 2862101 | 01 | GEMCITABINE/GENERICS | PD.SOL.INF | 200MG/ML | BTx1 VIALx200 MG | GENERICS PHARMA HELLAS ΕΠΕ | Χ | |||||||
99 | 2862102 | 01 | GEMCITABINE/GENERICS | PD.SOL.INF | 1000MG/VIAL | BTx1 VIALx1000 MG | GENERICS PHARMA HELLAS ΕΠΕ | Χ | |||||||
100 | 2836201 | 01 | MEDIGEM | C/S.SOL.IN | 10MG/ML | BTx1 VIALx20 ML | EBEWE PHARMA GES.M.B.H NFG.KG, AUSTRIA | Χ |